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The Gag–Pol polyprotein of the human immunodeficiency virus type 1 (HIV-1) is the precursor of the virus enzymatic activities and is
produced via a programmed 1 translational frameshift. In this study, we altered the frameshift efficiency by introducing mutations within the
slippery sequence and the frameshift stimulatory signal, the two elements that control the frameshift. These mutations decreased the frameshift
efficiency to different degrees, ranging from ¨0.3% to 70% of the wild-type efficiency. These values were mirrored by a reduced incorporation of
Gag–Pol into virus-like particles, as assessed by a decrease in the reverse transcriptase activity associated to these particles. Analysis of Gag
processing in infectious mutant virions revealed processing defects to various extents, with no clear correlation with frameshift decrease.
Nevertheless, the observed frameshift reductions translated into equivalently reduced viral infectivity and replication kinetics. Our results show
that even moderate variations in frameshift efficiency, as obtained with mutations in the frameshift stimulatory signal, reduce viral replication.
Therapeutic targeting of this structure may therefore result in the attenuation of virus replication and in clinical benefit.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV-1; 1 ribosomal frameshifting; Gag–PolIntroduction
The human immunodeficiency virus type 1 (HIV-1) encodes
its structural and enzymatic components from the overlapping
gag and pol open reading frames, respectively (reviewed in
Frankel and Young, 1998; Freed and Martin, 2001; Tang et al.,
1999). When ribosomes of infected cells translate the full-
length viral messenger RNA, Gag is synthesized according to
conventional rules of decoding, whereas Pol is produced from
the same messenger as a Gag–Pol precursor via a programmed
1 ribosomal frameshift event. The frequency of this event
was assessed at 2–10%, depending upon the system used to0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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nikolaus.heveker@recherche-ste-justine.qc.ca (N. Heveker).measure it (Biswas et al., 2004; Cassan et al., 1994; Dulude et
al., 2002; Grentzmann et al., 1998; Harger and Dinman, 2003;
Jacks et al., 1988; Reil et al., 1993). The programmed 1
ribosomal frameshift is widely used by viruses to produce
Gag–Pol (reviewed in Brierley, 1995). It allows a precise
control of the Gag–Pol to Gag ratio and also ensures the
incorporation of the viral enzymes upon assembly of the
viruses due to the fusion of the Pol sequence to Gag. The HIV-
1 Gag polyprotein, p55, is the precursor of various endproducts
that result from proteolytic breakdown by the HIV-1 protease.
These are the matrix (MA or p17), the capsid (CA or p24), the
p2 spacer peptide (SP1), the nucleocapsid (NC or p7), the p1
spacer peptide (SP2), and p6 (reviewed in Frankel and Young,
1998; Freed and Martin, 2001; Tang et al., 1999). Gag–Pol
shares proteins MA to NC with Gag, but not p1 and p6 because
of the frameshift event that overlaps with the p1 reading frame.
These two proteins are replaced in Gag–Pol by a transframe
(TF) octapeptide and p6*, the roles of which are still6) 127 – 136
www.e
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references therein). The Pol portion of Gag–Pol contains the
three enzymes that are essential for the replication of the virus:
the protease (PR), which cleaves the Gag and Gag–Pol
polyproteins, producing mature proteins, the reverse transcrip-
tase (RT), which converts the viral RNA genome into a proviral
DNA duplex, and the integrase (IN), which inserts the proviral
DNA into the host chromosome (Frankel and Young, 1998;
Freed and Martin, 2001; Tang et al., 1999). The Gag
polyprotein directs assembly and release of new virions from
infected cells (reviewed in Freed, 1998). During or after the
release, the viral protease cleaves the Gag and Gag–Pol
polyproteins, producing mature, infectious viral particles.Fig. 1. Frameshift region of wild-type HIV-1 and its mutants. (A) HIV-1 gag and po
ribosomal frameshift region. The pol gene is in the 1 frame relative to gag and it i
frameshift stimulatory signal of HIV-1 and summary of the mutations introduced in
stimulator consisting of a long irregular stem-loop, where the upper and the lowe
sequences of wild-type HIV-1 and its derivatives mutated in the frameshift region.
between the end of p7 (nucleocapsid) and the beginning of p6. The slippery sequ
nucleotide residues that are not altered in the Gag mutants (M1 to M8) are represePrevious studies of the 1 programmed frameshift events
demonstrated the requirement of two mRNA cis-acting
elements for efficient frameshifting (reviewed in Brierley and
Pennell, 2001) (see Figs. 1A and B). In HIV-1, the first
element is a heptamer sequence UUUUUUA, called the
slippery sequence, where the 1 frameshift occurs. The
second element is a long helix structure located immediately
downstream of the slippery sequence, which stimulates the
frameshift. This structure, which contains two stems separated
by a purine-rich bulge, was first characterized by probing with
enzymatic attack and mutagenesis (Dulude et al., 2002) and
recently confirmed by NMR (Gaudin et al., 2005; Staple and
Butcher, 2005).l open reading frames. The overlapping segment contains the programmed 1
s expressed as a Gag–Pol polyprotein via a 1 frameshift. (B) Structure of the
the frameshift region. The underlined slippery site is followed by a frameshift
r stems are separated by a three-purine bulge. (C) Amino acid and nucleotide
The elements required for the frameshift are located in the p1 spacer peptide,
ence is underlined in the wild-type nucleotide sequence (wt). Amino acid and
nted by dashed lines.
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established, several questions remain to be answered in order
to exploit the frameshift event as a potential drug target. In
particular, it remains to determine the extent to which
variations in frameshifting efficiently translate into reduced
viral replication and therefore into potential clinical benefit.
Biswas et al. (2004) found that replacing the slippery sequence
of HIV-1 with other slippery sequences severely decreases
frameshifting and viral infectivity. However, the slippery
sequence most likely does not form a defined structure, making
specific interactions with candidate compounds difficult. In
contrast, targeting of the frameshift stimulator structure by
small molecules may be envisioned. A report by Telenti et al.
(2002) analyzed natural and laboratory HIV-1 isolates with
sequence variations in the upper stem of the stimulatory signal
and found reduced viral replication only for two variants with
more than 60% reduction in frameshift efficiency, whereas
variants with a 16–42% reduction did not show any detectable
replication deficit. The interpretation of these data suggested
the existence of a threshold of tolerance for frameshift
variations under which they would have no effect on viral
replication. This in turn implied that attempts to modulate
frameshift would be of no therapeutic value unless efficiently
overcoming this threshold.
The present study was designed to elucidate the impact of
mutations in the two cis-acting elements of the HIV-1
frameshift region on both frameshifting efficiency and viral
replication. We introduced mutations into the slippery site, the
upper stem and the lower stem of the stimulatory signal
structure. The effects of these mutants cover a wide range of
frameshift efficiencies that were paralleled by a decreased
infectivity of mutant virions and a reduced replication in long-
term cultures. Our results show that moderate reductions of
frameshift efficiency are able to slow down viral replication,
which suggests that compounds causing such reductions should
provide clinical benefit.
Results
Description of HIV-1 mutants altered in the frameshift region
In order to study the influence of changes in frameshift
efficiency on HIV-1 replication, we investigated eight mutants
containing mutations within the slippery sequence and/or the
stimulatory frameshift signal. Fig. 1 shows the HIV-1 wild-type
frameshift region and describes the mutants M1 to M8.
Mutants M1 to M5 contain mutations that alter the slippery
site and influence the frameshift efficiency by changing the
dynamics of the codon–anticodon interaction at the A and/or P
site. Mutants M1 (UUUUUUU), M2 (UUUAAAA), and M3
(UUUUUUG) have a mutated A-site codon. M5 is mutated in
both the A- and P-site codons of the slippery site, the sequence
that replaces the HIV-1 slippery sequence being AAAAAAC,
which is used as a frameshift slippery site by several viruses
(see below in the Discussion section). Mutant M4, for which
the UUUUUUA slippery sequence was substituted with
CUUCCUC, served as a negative frameshift control since itdoes not allow slippage of the two tRNAs and re-pairing in the
1 frame.
The other mutants are altered in the frameshift stimulatory
signal. Mutant M6 is destabilized in the lower stem and M7 in
the upper stem of the signal. M8 has mutations that increase the
thermodynamic stability of this upper stem by replacing two
U–A pairs with two C–G pairs, in addition to having a C–G
instead of a UIG pair on top of this stem and having the M1
mutation. This mutant was initially designed to increase
frameshifting.
Frameshift efficiency of the HIV-1 mutants altered in the
frameshift region
The frameshift efficiency of wild-type and mutant constructs
was measured with a dual-luciferase system (Fig. 2). The wild-
type HIV-1 frameshift region caused a frameshift with an
efficiency of 9 T 1% in this system, which is in agreement with
previous studies that measured HIV-1 frameshifting with
similar reporter systems (Biswas et al., 2004; Harger and
Dinman, 2003). The frameshift efficiency of the negative
control (M4) was reduced to a background level, as expected.
For mutant M1, the frameshift efficiency was 48% of the wild-
type whereas for M2 and M3 the frameshift was 8% and 60%
of the wild-type, respectively. When the slippery site of HIV-1
was changed to the AAAAAAC sequence (M5) used by other
viruses, the frameshift efficiency decreased to 35% of the wild-
type construct. Destabilization of the lower stem (M6) led to a
frameshift level of 70% and destabilization of the upper stem
(M7) to 23%. Finally, with mutant M8, designed to stabilize the
upper stem, the frameshift efficiency decreased to 42% of the
wild-type value. Therefore, all the eight mutations decreased
the frameshift efficiency to variable degrees.
Influence of frameshift mutations on virus-like particles (VLPs)
We then investigated how changes in frameshift efficiency
might affect the release of VLPs and the incorporation of Gag–
Pol in these particles. As shown in Fig. 3, no mutation of the
frameshift region altered the quantity of released p24.
However, we observed changes in the amount of RT activity
present in the VLPs and consequently in the ratio of Gag–Pol
to Gag incorporated. These variations correlated perfectly with
the changes in frameshift efficiency. Those mutations that most
dramatically decrease the frameshift efficiency cause the largest
decrease in the amount of Gag–Pol incorporated (see the inset
of Fig. 3).
Influence of changes in frameshift efficiency on Gag processing
The processing of the Gag polyprotein is mediated by the
viral protease contained within Gag–Pol. We therefore
investigated the effect of frameshift changes on the maturation
of Gag within virions produced from cells transfected with the
mutant derivatives of HIV-1LAI altered in the frameshift region.
The assay consisted in assessing the amount of the capsid
protein, p24, produced upon Gag processing. As shown in Fig.
Fig. 2. Measurement of the frameshift efficiency of HIV-1 derivatives with a dual-luciferase system. (A) Scheme of the vectors used to measure the frameshift
efficiency. In the pDual-HIV construct, the HIV-1 wild-type or mutant frameshift region (FR) is inserted between the Renilla luciferase (Rluc) gene and the firefly
luciferase (Fluc) gene. With the pDual-HIV(1) construct, the firefly luciferase (Fluc) is synthesized as a fusion to the Renilla luciferase (Rluc) only by ribosomes
that make a 1 frameshift in the inserted frameshift region. Plasmid pDual-HIV(0) is an in-frame control, in which an additional adenine is inserted immediately
after the slippery site. With this construct, Fluc is synthesized as a fusion to Rluc only by ribosomes that translate the messenger according to conventional rules.
Frameshift efficiencies were determined by dividing the ratio of the firefly to Renilla luciferase activities from the wild-type or mutant constructs by the firefly to
Renilla luciferase ratio from the in-frame pDual-HIV(0) control construct. (B) Frameshift efficiency of the frameshift mutants. 293FT cells were transfected with the
different dual-luciferase constructs and the activities of Renilla and firefly luciferase were measured 48 h later. The frameshift efficiencies are indicated relative to the
wild-type construct, which is arbitrarily set at 100% (the absolute value is 9 T 1%). Each value represents the mean T standard deviation of at least four independent
experiments.
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virions but there was no detectable Gag processing for mutants
M2 and M4, which have a very low frameshift efficiency. The
Gag processing was decreased about twofold compared to the
wild-type virions for mutants M1, M3, M6, M7, and M8,
which have frameshift efficiencies ranging between about 23%
and 70% of the wild-type value, and mutant M5, with a
frameshift efficiency of 35%, had a decrease of about fivefold
in Gag processing. Similar profiles were obtained when
analyzing Gag processing within VLPs produced from COS-
7 cells transfected with pGAGPOL-xm-wt and its mutant
derivatives (data not shown). These Gag processing profiles
suggest a lack of proportionality between the decrease in
frameshift efficiency and processing. Indeed, mutants M6 and
M7, with, respectively, a frameshift efficiency of 70% and 23%of the wild-type value, had a reduction of 50% in the
production of the p24 breakdown product.
Influence of changes in frameshift efficiency on viral infectivity
We also investigated the effect of changes in frameshift
efficiency on the infectivity of HIV-1 by performing single-
round infectivity assays. Infectivity is the relative number of
infectious units per standardized p24 content in the inoculum.
As shown in Fig. 5, the infectivity of virions produced from
cells transfected with the mutant derivatives of HIV-1LAI with
an altered frameshift region was inferior to that of the wild-type
construct. The decrease in infectivity was proportional to the
decrease observed in frameshifting, the effect on viral
infectivity being slightly amplified. One apparent exception
Fig. 3. Effect of changes in frameshift efficiency on the release of VLPs, on the RT content of the released VLPs, and on the ratio of Gag–Pol to Gag in these VLPs.
Four micrograms of pGAGPOL-xm-wt or pGAGPOL-M1 to -M8 and 2.5 Ag of pRev1 were introduced into COS-7 cells by transfection. The p24 and the RT content
of the VLPs in the culture supernatant were measured 64 h posttransfection (see details in Materials and methods). White and grey bars represent, respectively, the
p24 and the RT level of the VLPs released in the supernatant. Black bars represent the ratio of RT to p24 for the released VLPs. Changes in the amount of released
p24, RT and in the RT to p24 ratio for the mutants are indicated relative to the wild-type construct, which is arbitrarily set at 100%. The inset presents the correlation
(R2 = 0.923) between the RT to p24 ratio and the frameshift efficiency (Fs) of the wild-type construct and frameshift mutants. Each value represents the mean T
standard deviation of three to four experiments.
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non-infectious, despite an appreciable frameshift efficiency and
RT incorporation in VLPs.
Influence of changes in frameshift efficiency on viral
replication
In order to investigate whether the observed decrease in
frameshift efficiency and the reduction in infectivity would
cause cumulative effects in long-term cultures, we analyzed the
replication kinetics of mutants M1 to M8 in CEM T-cells (see
Fig. 6). With mutants M2, M4, and M5, there was no detectable
virus production during the period of observation and the
replication of mutants M1, M7, and M8 was severely
attenuated as compared to the wild-type control HIV-1LAI.Fig. 4. Analysis of the processing of Gag within virions mutated in the
frameshift region. Virion samples produced from provirus transfection in HeLa-
P4 cells were resolved by a 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and probed by Western blot with an anti-p24 antibody. A
representative blot from three separate experiments is shown. P55 (Gag)
corresponds to the non-processed polyprotein, whereas p24 (CA) represents a
mature component of the processed Gag. The wt lane corresponds to the wild-
type protein profile, and lanes M1 to M8 correspond to the frameshift mutants.
The ratio of p24 to p55 in the wild-type and mutant virions is indicated under
each lane, expressed as the percentage of processing in wild-type virions.Interestingly, the p24 production of mutant M6 was less than
50% of that of the wild-type virus at all time points, indicating
reduced viral replication in spite of a moderate effect on
frameshift efficiency. Finally, mutant M3 also produced less
p24, and the peak of production was delayed by more than 3
days as compared to the control. These results demonstrate that
all mutants with altered frameshift efficiency were appreciably
attenuated in long-term virus replication.
Discussion
In the present work, we introduced mutations in the
frameshift slippery site and in the downstream frameshift
stimulatory signal of HIV-1. Our study shows that even
relatively mild effects on frameshift efficiency, such as those
resulting from mutations in the frameshift stimulatory signal,
lead to a reduced replication of the mutant virions. The
frameshift stimulatory signal has a defined structure with which
antiviral compounds could interact, unlike the slippery site,
which may be a more difficult target. Indeed, even the
replication of mutants for which no dramatic changes in Gag
processing were detected by Western blot analysis was affected
in comparison to the wild-type virus. Therefore, and in contrast
to the view expressed by Telenti et al. (2002), our results
suggest that any change in frameshift efficiency results in
reduced viral replication and that no threshold of frameshift
alteration must be reached to become phenotypically manifest.
In addition to showing a strong correlation between
frameshift and virus replication, our results yield new
information on the different elements of the frameshift region.
Destabilization of the lower stem of the HIV-1 frameshift
stimulatory signal (M6) results in a mild but clearly detectable
Fig. 5. Single-round infectivity assays with HIV-1 and its derivatives mutated in the frameshift region. HeLa-P4 cells were infected with p24-normalized amounts of
wild-type HIV-1LAI or mutant viruses. Changes in the infectivity of the mutant viruses (M1 to M8) are indicated relative to the wild-type HIV-1 (wt), which is
arbitrarily set at 100%. The inset presents the correlation (R2 = 0.752) between the infectivity and the frameshift efficiency (Fs) of the wild-type virus and the
frameshift mutants. Each value represents the mean T standard deviation of a triplicate analysis.
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drastically reduces the replicative capacity of the mutant virus.
In contrast to mutants M6 and M7, mutant M8 stabilizes the
upper stem but it nevertheless results in a decreased frameshift
efficiency and in a dramatic decrease in the replicative capacity
of the corresponding mutant virus. Interestingly, Bidou et al.
(1997) also reported that increasing the stability of the upper
stem decreases the frameshift efficiency of HIV-1 and
concluded that increasing the pause of the ribosome on the
slippery site disfavors the frameshift. Our results illustrate the
importance of maintaining the structural integrity and stability
of the frameshift stimulatory signal for the infectivity of the
virus but they contrast with the results of Telenti et al. (2002).
Indeed, these researchers failed to detect reduced infectivity or
replication for variants containing substitutions that destabilize
the upper stem of the frameshift stimulatory signal and reduce
frameshift efficiency to a value of about 60% compared to
wild-type. However, they observed a reduced infectivity for
two mutants with a frameshift efficiency decreased at andFig. 6. Replication kinetics of HIV-1 and mutants with an altered frameshift efficien
1LAI (wt) or mutant viruses. Viral replication was monitored at regular intervals by
ELISA assay. Mutants M2, M4, and M5 replicate below the level of detection of tbelow 40% of the wild-type. Telenti et al. concluded that this
40% value constitutes a threshold efficacy, above which
variations in frameshifting have no effect on viral replication.
The reason for this discrepancy between our results and those
of Telenti et al. is unclear and may lie in differences between
the respective experimental systems.
We introduced five mutations that alter the slippery
sequence, M1 to M5. For mutant M1 (with a stretch of 7U),
we detect a 50% reduced frameshift efficiency. With the 7U
sequence (M1 and M8), frameshifting occurs with a tRNAPhe
in the A-site rather than a tRNALeu as it is the case for the wild-
type. It is possible that tRNAPhe is less prone to slip than
tRNALeu. Similarly, for UUUAAAA (M2), it is also possible
that tRNALys in the A-site is less prone to slip than tRNALeu.
The importance of the identity of the tRNA for the frameshift
efficiency is also supported by previous observations from
Chamorro et al. (1992). A change in the identity of the A-site
tRNALeu (from tRNALeu with an IAG anticodon to a tRNALeu
with a CAG anticodon) also likely accounts for the decreasedcy. CEM T-cells were infected with p24-normalized amounts of wild-type HIV-
quantification of the p24 concentration in the culture supernatant with a p24
he assay. A representative analysis from three separate experiments is shown.
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Brierley et al., 1992). The AAAAAAC sequence (M5) contains
a slippery sequence found in astroviruses, in human T-cell
leukemia virus type 2, in mouse mammary tumor virus
(MMTV), and in equine anemia infectious virus (EIAV)
(reviewed in Brierley, 1995). The frameshift efficiency of M5
is 35% of the wild-type, in agreement with Biswas et al.
(2004), who also replaced the slippery sequence of HIV-1 with
AAAAAAC. Interestingly, it has been reported that replacing
the AAAAAAC sequence of EIAV with the slippery sequence
of HIV-1 decreased the frameshift efficiency to 50% in the
presence of the pseudoknot that acts as a frameshift stimulator
in EIAV (Chen and Montelaro, 2003). Therefore, some degree
of functional interdependence seems to exist between the
slippery sites and a matching stimulatory signal since both
elements cannot be arbitrarily interchanged between viruses.
All the mutations that were introduced in the slippery site
severely decreased the capacity of the virus to replicate, the
severity of this effect correlating with the decrease in the
frameshift efficiency, with the exception of M5 (see below).
The mechanisms accounting for the observed effects of the
frameshift mutations on HIV-1 replication may be multiple.
The frameshift changes result in reduced Gag–Pol production
and consequently reduced incorporation of the viral enzymes
into the virions. The amount of RT activity within VLPs
directly mirrors reduced frameshift efficiency, and it is likely
that the decreased RT amount largely contributes to the
decreased viral infectivity, knowing that viral infectivity is
very sensitive to changes in RT activity (see Ambrose et al.,
2004; Julias et al., 2001). The reduction in Gag–Pol
incorporation can result in altered protease activity leading to
altered Gag processing, but it appears that protease activity
must be reduced by more than fourfold to significantly impair
viral infectivity (Rose´ et al., 1995). We therefore do not believe
that maturation defects play a major part in the reduced
infectivity observed for the mutant viruses, except when the
amount of protease is dramatically decreased (mutants M2 and
M4) and in the case of mutant M5 (see below). It is also
possible that the decreased integrase incorporation contributes
to reduce the infectivity of mutant viruses. In addition,
mechanisms other than just the reduction of incorporated viral
enzymes may be at work. It has been shown that over- or
underexpressing Gag–Pol impairs the maturation of the virion
genomic RNA dimers (Shehu-Xhilaga et al., 2001, 2002), and
it can be hypothesized that such an impairment could
contribute to the decreased infectivity of mutant viruses. Also,
the incorporation of tRNALys into viruses is a crucial event in
the viral replication cycle, which is driven by Gag–Pol (Mak et
al., 1994) and could be affected by a decrease in Gag–Pol.
The strong correlation that we observe between the decrease
in frameshift efficiency and the decrease in viral infectivity
supports our interpretation that the changes in the amount of
Gag–Pol produced in the mutants investigated account for the
decrease in viral infectivity. However, other changes besides the
decrease in frameshift efficiency and the resulting reduction in
Gag–Pol production could also contribute to lower the virus
infectivity. For example, it could be hypothesized that themutations that we introduced in the frameshift region influence
the secondary and tertiary structure of the viral RNA. These
structural changes could perturb long-range interactions such as
those involved in the stabilization of the association between the
two copies of genomic viral RNA forming a dimer (Hibbert and
Rein, 2005; Paillart et al., 2002, 2004). Mutants M1 and M3
have a comparable frameshift efficiency, a comparable level of
RT activity associated to the VLPs and do not differ in Gag
processing. However, M1 appears to be less infectious than M3
by about twofold. Although purely speculative, an effect of the
mutation in M1 on the viral RNA secondary and tertiary
structure could account for its lower infectivity compared to
M3. Also, it is difficult to mutate the frameshift signal of HIV-1
without simultaneously changing the amino acid sequence of
the corresponding Gag p1 spacer peptide and that of the p7/p1
and p1/p6 cleavage sites, which might also affect viral
replication. For example, two proline residues (positions 7
and 13) of the 16-amino acid p1 have been shown to be required
for efficient HIV-1 infectivity (Hill et al., 2002). Interestingly,
the only frameshift mutants found to have reduced replication
by Telenti et al. (2002) contain a proline to lysine substitution at
position 7. It could therefore be envisioned that the experimen-
tal conditions used by Telenti et al. were able to detect defects
due to p1 mutations but were not sensitive enough to identify
more subtle effects due to frameshift variations. The impact of
some p1 mutations on the viral replication is also illustrated by
the drastic phenotype of our mutant M5. This mutant contains
three amino acid substitutions at the p7/p1 protease cleavage
site, among which the introduction of a lysine residue at the P1
position of this cleavage site, a substitution that was previously
shown to abolish the cleavage reaction (Pettit et al., 2002). It
could be suggested that these substitutions at the p7/p1 cleavage
site affect the overall protease activity. The observed decrease of
protease activity of mutant M5 could indeed contribute to lower
its infectivity, which is also disproportional to the effect of the
mutation on frameshifting. We should, however, point out that
this observation applies only to mutant M5, and it is unlikely
that p1 mutations have a major influence on the phenotypes of
all our mutants. For example, the mutation of M3 does not affect
the amino acid sequence of p1, yet affects viral replication.
Altogether, our study provides evidence that variations in the
frameshift stimulatory signal lead to moderate reductions of
frameshift efficiency but nevertheless reduce the replicative
capacity of the virus. Even a partial reduction of virus replication
can translate into clinical benefit. This seems indeed to be the
case for many drug-resistant HIV-1 strains that bear mutations
reducing their replicative fitness (Berkhout, 1999). Reduction of
viral replication by compounds targeting the stimulatory signal
may thus be of significant therapeutic interest.
Materials and methods
Construction of plasmids
pGAGPOL vectors
The HIV-1 gag–pol expression vector used in this study for
the synthesis of virus-like particles (VLPs) was derived from
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the SV40 promoter, the gag–pol gene and the rev-responsive
element (RRE) from the HIV-1 proviral clone BH10-HXB2
(Smith et al., 1990). Cotransfection in COS-7 cells (see details
below) of this plasmid together with pRev1 (Smith et al.,
1990), which codes for HIV-1 Rev, results in the efficient
release of VLPs in the culture supernatant of the transfected
cells. To facilitate the cloning of mutants of pGAGPOL-RRE-r
altered in the frameshift region, we created a cloning derivative
of this plasmid, named pGAGPOL-xm. In this plasmid, the
frameshift region was deleted and replaced with a short cassette
containing a XhoI restriction site at one end and a MluI
restriction site at the other end. This was made by PCR
amplification with a standard overlap extension procedure (Ho
et al., 1989). The wild-type construct and the frameshift
mutants were made by inserting, between the digested XhoI
and MluI sites of pGAGPOL-xm, the appropriate annealed and
phosphorylated 74-bp oligonucleotide cassette, purchased from
Sigma Genosys. This generated pGAGPOL-xm-wt and pGAG-
POL-M1 to pGAGPOL-M8, respectively (Fig. 1C). The
insertion of a XhoI and a MluI restriction site in pGAGPOL-
xm-wt and its derivatives substituted a tyrosine with a lysine
residue and a proline with a valine residue at the amino acid
position 427 and 453 of Gag, respectively. These modifications
did not change the reverse transcriptase (RT)-associated
content of the released VLPs compared to the parental
construct (data not shown).
Dual-luciferase reporter plasmids
A dual-luciferase reporter plasmid was created, based on
previously published systems (Grentzmann et al., 1998; Harger
and Dinman, 2003). Briefly, the HIV-1 frameshift region was
inserted between the coding sequence of the Renilla luciferase
(Rluc) and the firefly luciferase (Fluc) gene in an appropriate
vector. In this construct, only the ribosomes that initiated
translation at the initiator codon for the Renilla luciferase but
changed the reading frame by one base in the 5V direction in the
frameshift region synthesize the firefly luciferase, which is thus
fused to Renilla luciferase (see Fig. 2A). To create this vector,
the Renilla luciferase coding sequence and part of its 5V
untranslated region were amplified by PCR from pRluc-C1, a
Renilla luciferase fusion protein expression vector (a generous
gift from Dr. M. Aubry, Universite´ de Montre´al). The forward
and reverse mutagenic primers: 5VGCTGGTTTAGTGAAGCQ
TTCAGATCCGCTAGAGCCACC-3V and 3VAACGAGCAGQ
GGGGTACCCGGCGAGCTCTCV5 used for this amplification
introduced a HindIII and a KpnI restriction site at the 5V and 3V
end of the gene, respectively. The amplified Rluc gene was then
inserted upstream of the Fluc gene of HindIII–KpnI-digested
pcDNA3.1-luc (Dulude et al., 2002), generating the parental
pDual-luc construct. The wild-type and the mutated frameshift
regions (nucleotides 2037–2139 according to HXB2 genome
nomenclature) were amplified by PCR from pGAGPOL-xm-wt
or pGAGPOL-M1 to pGAGPOL-M8 and inserted between the
Rluc and Fluc genes of pDual-luc, generating pDual-HIV(-1)
and the pDual-HIV-M1 to pDual-HIV-M8 constructs, respec-
tively. The amplification used the following primers: Fwd-KpnI(5V-GGGCTGTTGGTACCTGGAAAGGAAGG-3V) and Rev-
BamHI (5V-GGGCTGTTGGATCCCACGCGTGACTG-3V),
and the digested PCR products were then inserted between
the KpnI and BamHI restriction sites of pDual-luc. All these
constructs were used to measure the level of firefly luciferase
expressed relative to the Renilla luciferase. An in-frame plasmid
control, pDual-HIV(0), in which the Rluc gene is in the same
frame as the Fluc gene, was created by PCR amplification. This
was made by inserting an adenine immediately after the slippery
site, which was mutated from UUUUUUA to CUUCCUC to
prevent 1 frameshifting, as described by Grentzmann et al.
(1998). This plasmid was used to measure the translation level
of the in-frame Fluc coding sequence relative to that of the Rluc
gene (see Fig. 2A).
Proviral clones
For infectivity assays, we used the LAI proviral clone,
which contains the complete genome of HIV-1LAI (Peden et al.,
1991). The wild-type construct, pLAI-wt, and the frameshift
mutants, pLAI-M1 to pLAI-M8, were LAI-BH10 chimeras
made by substituting a 1.2-kb AgeI-Bst1107I fragment from
the pGAGPOL-xm-wt and pGAGPOL-M1 to pGAGPOL-M8
plasmids, respectively, into the AgeI- and Bst1107I-digested
LAI proviral clone. With the inserted AgeI–Bst1107I BH10
fragment, amino acid residues 389, 401, 427, 453, and 473 of
Gag and residues 19–22 and 53 of Pol, were changed,
compared to wild-type HIV-1LAI.
Frameshift assays
The effect of the mutations on the 1 frameshift efficiency
was measured using the dual-luciferase reporter plasmids
described above. Frameshifting was monitored by transient
transfection of the dual-luciferase vectors into 293FT cells
(Invitrogen). The day before transfection, 2  104 cells/well
were seeded in 24-well plates and maintained in Dulbecco’s
modified Eagle medium (DMEM, Gibco) supplemented with
10% fetal bovine serum (FBS, Wisent). Briefly, 0.5 Ag of each
dual-luciferase reporter construct was transfected into cells,
using a standard calcium phosphate precipitation method
(Jordan et al., 1996), and cells were grown for 48 h before
being harvested. Cells were washed twice with PBS and lysed
with 100 Al of the Cell Passive Lysis Buffer (Promega). The
firefly versus the Renilla luciferase activities of each construct
were measured as relative light units with a Berthold Lumat LB
9507 luminometer, using a Dual-Luciferase Reporter Assay
System kit from Promega.
Production of VLPs
COS-7 cells (3  105 per plate) were plated in 60-mm
dishes and cultured in 4 ml of DMEM supplemented with 10%
FBS for 24 h prior to transfection. Four micrograms of
pGAGPOL-xm-wt or its mutant derivatives and 2.5 Ag of
pRev1 were introduced in cells by transfection, using a
standard calcium phosphate precipitation method. The culture
medium was removed and replaced with fresh medium 16
D. Dulude et al. / Virology 345 (2006) 127–136 135h posttransfection. Cells and supernatants were harvested 64
h posttransfection. The culture medium was centrifuged at
3000 rpm for 20 min at 4 -C to remove cellular debris. The
clarified medium was centrifuged again for 1 h at 40,000 rpm
(Beckman 50Ti rotor) to pellet the VLPs. Pelleted VLPs were
resuspended in 200 Al of 10 mM Tris–HCl (pH 7.5) and frozen
at 80 -C or used immediately. In parallel, cells were washed
twice with 2 ml of PBS and lysed with 1 ml of 1% Triton X-
100/PBS. Cell lysates were collected and stored at 80 -C or
used immediately.
RT assays
VLP-associated RT levels were assayed by a standard
procedure (Smith et al., 1990). In a 100-Al reaction volume, 65
Al of VLPs resuspended in the Tris buffer were incubated for
90 min at 37 -C with 4 ACi of H3-TTP (Perkin-Elmer) and 2.5
Ag of polyAdT(12–18) (Pharmacia) in an RT buffer at a final
concentration of 50 mM Tris–HCl (pH 7.4), 60 mM KCl, 2
mM DTT, 5 mMMgCl2, 0.1% Triton X-100, and 1 mM EDTA.
The reaction products were precipitated for 1 h on ice with 1 ml
of cold 10% (w/v) trichloroacetic acid containing 10 mM
sodium pyrophosphate, collected by filtration on glass-fiber
filters and counted for radioactivity.
p24 ELISA assays
p24 ELISA assays were performed to measure the amount
of Gag inside the cells and in the VLPs released in the
supernatant following the transfection of COS-7 cells with the
pGAGPOL vectors. Quantification of p24 was also used to
normalize the input of viruses in the infectivity assays and to
determine the amount of viruses produced in the replication
kinetics studies. These assays were performed using a
commercially available p24 antigen detection kit (Beckman-
Coulter), according to the instructions provided by the
manufacturer. In each experiment, a standard curve was
generated, using serial dilutions of a p24 standard. Samples
were diluted so that the experimental values were within the
linear range of the assay.
Virus production
HeLa-P4(CD4+/LTR-lacZ+) cells (Clavel and Charneau,
1994), which contain the lacZ gene under the control of the
HIV-1 LTR promoter, were used for virus production and
single-round infectivity experiments (see below). HeLa-P4
cells (8  105 cells/well) were seeded in 6-well plates and
cultured in DMEM supplemented with 10% FBS for 24
h before transfection with 5 Ag of proviral DNA, using the
Polyfect Transfection Reagent (Qiagen). The medium was
changed 24 h after transfection. Virus-containing supernatants
were collected 48 h posttransfection, clarified of cells debris by
a 5-min centrifugation (13,000 rpm), and stored at 80 -C. The
p24 content in the supernatants was determined by a p24
ELISA assay (see above) prior to the single-round infectivity
assays and to the long-term replication assays.Gag processing in virions
To examine the level of processing of Gag incorporated
into virions, 6 ml of supernatant from HeLa-P4 cells
transfected with proviral DNA were centrifuged at 25,000
rpm for 3 h at 4 -C through a 20% sucrose cushion with a
Beckman Coulter Avanti J25 centrifuge, using a JA.25.50
rotor. The viral pellets were resuspended in 200 Al of PBS
and 15 Al was resolved by electrophoresis on a 10% sodium
dodecyl sulfate–polyacrylamide gel. Samples were immuno-
blotted, using a mouse anti-HIV-1 p24 monoclonal antibody
(no 24-2), diluted 1/2000 (reagent obtained from Dr. Michael
Malim of the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH). Horseradish
peroxidase-conjugated sheep anti-mouse was used as the
secondary antibody. Antigen–antibody complexes were
detected by enhanced chemiluminescence and bands were
obtained with films (Biomax, XAR) exposed for a short
period. Bands were scanned and quantified with Quantity one
(Bio-Rad).
Single-round infectivity assays
HeLa-P4 cells were plated in 96-well plates (104 cells/
well) in DMEM supplemented with 10% FBS and infected
in triplicate with a normalized amount of HIV-1 or mutant
viruses (180 ng/ml of p24 of virus per well) for 24 h. The
supernatant was then removed, cells were lysed with lysis
buffer (0.2% Triton X-100/PBS), and h-galactosidase activity
was determined, using the chromogenic substrate chlorophe-
nolred-h-d-galactopyranoside, as described (Brelot et al.,
2000).
Replication kinetics of mutant virus
CEM T-cells were used for long-term replication experi-
ments. CEM T-cells (2  106) in 1 ml of RPMI 1640 medium
were infected with 360 ng/ml of p24 of wild-type or mutant
virus for 2 h, then washed and cultured in T-25 flasks with 5 ml
of fresh medium. The cultures were split every second day by
replacing 50% of the culture with the same volume of fresh
medium. Samples of culture supernatant were withdrawn from
the medium at regular intervals and p24 quantified as a
measure of ongoing virus replication.
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